ExLibris header image
SFX Logo
Title: Pediatric Drug–Drug Interaction Studies: Barriers and Opportunities
Source:

Clinical Pharmacology & Therapeutics [0009-9236] Salerno, Sara yr:2018


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Hennessy, S. "Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions." Clinical pharmacology & therapeutics 99.1 (2016): 92-100. Link to SFX for this item
2. Singh, S. "Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis." Alimentary pharmacology & therapeutics 43.9 (2016): 994-1003. Link to Full Text for this item Link to SFX for this item
3. "Adalimumab Versus Infliximab in Inducing Mucosal Healing in Moderate-to-Severe Ulcerative Colitis: A Cost-Per-Remission Decision Analytic Study." Gastroenterology : official journal of the American Gastroenterologic Association. 148.4. Link to SFX for this item
4. De Cruz, P. "Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis." Alimentary pharmacology & therapeutics 42.7 (2015): 867-79. Link to Full Text for this item Link to SFX for this item
5. Breban, M. "Risk of Tuberculosis Is Higher With Anti-Tumor Necrosis Factor Monoclonal Antibody Therapy Than With Soluble Tumor Necrosis Factor Receptor Therapy The Three-Year Prospective French Research Axed on Tolerance of Biotherapies Registry." Arthritis and rheumatism 60.7 (2009): 1884-1894. Link to Full Text for this item Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.